Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul class="summary-list"><li><keyword id="6409874" type="COMPANY" weightage="60" keywordseo="astrazeneca">AstraZeneca</keyword> on Saturday said it would acquire <keyword id="2186479" type="PERSON" weightage="60" keywordseo="Alexion">Alexion</keyword> Pharmaceuticals for $39 billion.</li><li>"Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology," said Pascal Soriot, chief executive of AstraZeneca, in <a href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html">a joint press statement</a>. </li><li>AstraZeneca said it had offered shareholders cash and stock worth about $175 per share, an about 45% premium from Friday's close at $120.98 per share. </li></ul>AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies' worldwide delivery pipelines, and establishing a new research headquarters in Boston. "Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology," said Pascal Soriot, chief executive of AstraZeneca, in <a href="https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-acquire-alexion.html">a joint statement</a>. The UK drugmaker offered Alexion shareholders a total of about $175 per share, a 46% premium over $120.98, where Alexion's American depositary shares closed Friday's session. Shareholders will receive $60 cash and 2.1243 AstraZeneca US shares, under the proposed deal, which will require US regulatory sign-off. Both boards unanimously approved the deal, which is expected to close in the third quarter of 2021. Alexion shareholders will hold about 15% of the combined company. Two members of Alexion's board will make the move to AstraZeneca's board."We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics," said Ludwig Hantson, chief executive of Alexion.AzstraZeneca on Saturday laid out a roadmap for the merger, saying the combined company will "drive future medicine innovation" in immunology, biologics, genomics, and olgonucleotides.Alexion's current management is expected to lead the company's rare-disease unit, and each Alexion employee can continue on at their current pay for a minimum of 12 months, according to Saturday's release. The joint roadmap also included a push into emerging markets, along with the establishment of a new research headquarters in Boston, a city with a cluster of research institutions and hospitals, where Alexion is based."AstraZeneca intends to build on its geographical footprint and extensive emerging markets presence to accelerate the worldwide expansion of Alexion's portfolio," the companies said. AstraZeneca said it expects about $650 million in new costs during the three-year integration period, followed by about $500 million per year of savings. If Alexion axes the deal, it'd be liable for a $1.2 billion payment to AstraZeneca, while the reverse would cost AstraZeneca $1.4 billion.In partnership with the University of Oxford, AstraZeneca has this year developed a COVID-19 vaccine, which is now <a href="https://www.businessinsider.com/pfizer-astrazeneca-oxford-covid-vaccine-combined-trial-covid-19-coronavirus-2020-12">being tested</a> by UK government regulators.When the company announced in November that its vaccine had succeeded in trials, some were quick to <a href="https://www.businessinsider.com/astrazenecas-covid-19-vaccine-trials-criticised-2020-11">raise questions</a> about the data that had been released. It had said the vaccine was 70% effective, but offered data <a href="https://www.businessinsider.com/astrazeneca-oxford-coronavirus-vaccine-news-problems-questions-data-2020-11?r=kd-sub">stitched together from multiple trials</a>, worrying some outside researchers.

AstraZeneca is acquiring Alexion Pharmaceuticals in a $39 billion pharmaceutical deal

In pharmaceuticals, the 20th century was the era of the small molecule. 
The industry thrived by identifying a steady stream of relatively simple compounds that treated lots of people, patenting them and making a fortune. 
In the early 21st century it has become harder for drugmakers to find new cures quickly enough to replace those on which the patents are expiring.
Many drugmakers, both established ones and startups, have sought salvation in biotechnology--the adaptation or exploitation of processes found inside living organisms.
As in other areas of drug research, there have been setbacks as well as successes. But steady progress is being made in creating "biologics", drugs that consist of giant molecules, hundreds of times the size of a conventional drug molecule, which are manufactured inside animal cells or micro-organisms such as bacteria. In the coming year a fresh wave of biologics is expected to be approved for use by general practitioners (see table).
Several of these will treat the millions of people who find that statins, the conventional treatment for high cholesterol, do not work well enough. Amgen's drug, evolocumab, may be first, followed by alirocumab, from Sanofi and Regeneron. Pfizer also has a contender, bococizumab, at an advanced stage of development.
Drugmakers have been encouraged to keep working on new biologics by the success of Humira, a treatment for rheumatoid arthritis and related conditions, which won approval in America in 2002 and is made by an American firm, AbbVie. Humira has become the world's leading prescription drug, with sales of $11 billion in 2013, according to EvaluatePharma, a research outfit.
Damien Conover of Morningstar, an investment-research firm, reckons that biologics provided 22% of the big pharma companies' sales in 2013, and he thinks this will rise to 32% by 2023. They will provide an even bigger share of revenues at those firms which have concentrated on them, such as Bristol-Myers Squibb, Merck, Eli Lilly and Sanofi. In America more than 900 biologics are in development, for more than 100 diseases.
Over the next five years, a further generation of biologic drugs will start to deliver cures by using viruses to deliver "gene therapy"--the replacement of a faulty gene in a patient's body cells with the correct version. China has had one such treatment, for some forms of cancer, since 2003. But in 2015 the West's first gene therapy, Glybera, for a rare genetic disease that clogs the blood with fat, will go on sale in Germany. The treatment, created by uniQure, a Dutch firm, is expected to cost EUR1.1m ($1.3m) for a course.
Pfizer has a new partnership with a biotech company, Spark Therapeutics, to give haemophiliacs the correct gene to produce blood-clotting factor. Scientists have already reported that ten patients with severe haemophilia B have remained cured for a number of years. Milo Biotechnology, another gene-therapy company, is developing treatments for muscle-wasting diseases such as muscular dystrophy.
Len Schleifer, the boss of Regeneron, which has several biologics close to approval, says the big advantage of such drugs is their specificity: they do only what they are supposed to do, rarely causing the sort of side-effects that are frequently discovered in conventional, small-molecule drugs, and lead to them being abandoned.
However, biologics are hard to make and, at present, difficult to take. They must be injected, infused or inhaled, as they are destroyed in the stomach when swallowed. This may discourage doctors from prescribing them in some cases. That said, José-Carlos Gutiérrez-Ramos, a senior scientist at Pfizer, says improvements will keep being made to how the drugs can be delivered. If so, biologics that can be popped as pills may be possible one day.
Biologics, like all other drugs, are not immune to setbacks. Shares in Roche, a Swiss drugs giant, fell sharply on December 19th when it disclosed disappointing results from tests on cancer patients of a combination of two of its biologics, Kadcyla and Perjeta. Four months earlier Britain's National Institute for Health and Clinical Excellence had decided that Kadcyla should not be prescribed routinely on the National Health Service for women with breast cancer, since its list price is around $140,000 a course.
As with all new drugs, it is not just a matter of how well a biologic works compared with existing treatments, but also whether it is affordable. Biologics for rheumatoid arthritis, which patients have to keep taking for the long term, cost more than $12,000 per patient a year. Some, like Humira, cost far more than this. Paying this sort of money is hard enough for rich countries' health systems; for poorer countries, it is out of the question.
As biologics increase their market share, their cost and efficacy will come under greater scrutiny. Already, the governments of Italy and France have noted that Avastin, a biologic developed for cancer, also treats macular degeneration, a cause of blindness. And it is far cheaper than Lucentis, a biologic for that condition sold by the same companies, Roche and Novartis. To its makers' chagrin, the two governments have approved the use of Avastin for macular degeneration, a move which, according to one French legislator, will save his country's health service $273m a year compared with using Lucentis.
When the patents on conventional drugs expire, other firms are free to start selling "generic" copies of the same chemical; and when the makers of biologics lose patent protection, rival companies are allowed to make equivalents of them, known as "biosimilars". This is harder than copying conventional drugs.
Furthermore, says Ben Perkins of EY, a consulting firm, biosimilars will be (as their name suggests) similar rather than identical: they may be significantly worse, or even better, than the original. In America, a lack of clarity in the regulations for the approval of biosimilars has slowed the development of a market for them, in those cases where biologics have come off patent.
However, things are beginning to move: for instance, in December Apotex, a Canadian firm, said America's Food &amp; Drug Administration (FDA) had agreed to consider its biosimilar of Neulasta, a biologic made by Amgen, an American firm, which helps cancer patients fight infection. A study published in November by the RAND Corporation, a research institute, said that on current assumptions about how the FDA's regulations will develop, biosimilars could save America's health system a total of $44 billion over the coming decade.
That would be a useful sum, but the overall savings from biosimilars will not be as dramatic as those from replacing branded conventional drugs with generic versions. First, biosimilars will also be costly to make. Second, since they will not be identical copies, doctors and patients may be slow to accept them as substitutes.
All this will be good news for those drugmakers who create successful biologics, for it will allow them to continue selling at higher prices for longer. They may thus find that the "patent cliff", the slump in revenues they have been suffering as older remedies lose patent protection, is not as steep as feared. But health-service bosses the world over will find that their job gets even harder than it is now: new treatments for once-intractable ailments will keep being invented, but their costs will be cripplingly high.
Click <a href="https://subscriptions.economist.com/nwcd">here</a> to subscribe to The Economist

Pharmaceuticals: Going Large

<keyword id="105572" type="CITY" weightage="100" keywordseo="glenmark-pharmaceuticals">Glenmark Pharmaceuticals</keyword> seeks shareholders' approval to raise up to USD 500 million (around Rs 3,300 crore) by issue of securities in domestic and international markets, it said in a <keyword id="35140" type="CITY" weightage="100" keywordseo="BSE">BSE</keyword> filing. 

	In order to capitalise on various opportunities for further growth of the business, the company intends to enhance its marketing network both in domestic and overseas market, set up manufacturing infrastructure, focus on R&amp;D and introduce new products across various markets, it added.
 

	"Therefore, it would be necessary for the company to raise funds in Indian and/or international markets in one or more tranches by issue of shares/securities, in one or more series of such securities (with different tenures)", the company said.
 

	The company is also seeking shareholders' consent for creation of charge/mortgage on assets of the company.
 

	The postal ballot ends on January 20, 2016.
 

	Glenmark has a significant presence in branded generics markets across emerging economies including India. Its subsidiary Glenmark Generics Ltd has a fast growing and robust US generics business.
 

	Glenmark has 16 manufacturing facilities in five countries and six R&amp;D centres and it employs over 11,500 strong workforce from around 50 nationalities.
 

	The company's shares were trading at Rs 929.35 apiece on the BSE, down 1.64 per cent from previous close.

	 
	 
	(Image credits: indiatimes)

Glenmark Pharmaceuticals seeks shareholders' approval to raise funds for its expansion plans

<ul class="summary-list"><li>Ferring Pharmaceuticals has suspended all shipments of its key fertility drug, Menopur.</li><li>Insider obtained a memo Ferring Pharmaceuticals sent to healthcare providers. </li></ul>Ferring Pharmaceuticals has suspended shipments of <a href="https://www.ferringfertility.com/our-fertility-offerings/">Menopur,</a> a drug used to treat infertility in women. Insider received a copy of a memo Ferring Pharmaceuticals' chief science officer Elizabeth Garner sent to healthcare providers on Wednesday, announcing the stoppage of Menopur shipments.Garner said "all shipments" of the drug have been suspended "due to changes made in the manufacturing process of Menopur drug substance by a third-party supplier." "We are currently reviewing this situation and will provide you with updates as appropriate," Garner wrote. She added that the company is working to address supply disruptions.A staff member at Ferring Pharmaceutical's Singapore division confirmed to Insider on Thursday that shipments of Menopur are suspended worldwide. The Ferring Pharmaceuticals staff member said they could not comment on when shipments would resume.Menopur is an injectable drug that is widely used to <a href="https://www.webmd.com/drugs/2/drug-92878/menopur-subcutaneous/details">treat infertility in women</a>. It triggers the release of eggs from ovaries in women who are not ovulating, per Menopur's <a href="https://www.medicines.org.uk/emc/files/pil.1294.pdf">patient information leaflet.</a> Women undergoing in-vitro fertilization <a href="https://d2hu1op93domjx.cloudfront.net/wp-content/uploads/sites/12/2021/06/24085313/Menopur-PI-Rev.-05.2018-20Mar2019.pdf">need doses of Menopur every day, for five days</a>.Garner wrote in her Wednesday memo that Ferring Pharmaceuticals is "not aware of any evidence" that the change in Menopur's manufacturing process will put patients at risk.Ferring Pharmaceuticals is headquartered in Switzerland. The company serves millions of people across 110 countries, per its <a href="https://ferringusa.com/about-ferring-usa/about-us/">website</a>.Garner did not immediately respond to Insider's requests for comment.

Ferring Pharmaceuticals has suspended shipments of a key fertility drug, Menopur

<ul><li>Amidst the Sebamed-HUL Soap war, <keyword id="2607224" type="UNKNOWN" weightage="20" keywordseo="Brinton-Pharmaceuticals">Brinton Pharmaceuticals</keyword> launches a new <keyword id="10698566" type="UNKNOWN" weightage="20" keywordseo="neobar-soap-digital-ad">Neobar Soap Digital Ad</keyword>.</li><li>It takes a dig at the giants for fixating on <keyword id="4729765" type="PERSON" weightage="20" keywordseo="pH-levels">pH levels</keyword> and sexualising women. </li></ul>In a smart move, Brinton Pharmaceuticals has launched a digital film about its Neobar Moisturizing Soap as an addition to the soap war between Sebamed and <keyword id="44863" type="CITY" weightage="20" keywordseo="HUL">HUL</keyword>. The story so far is that Sebamed had slyly released a TVC that compared the PH levels of its soap with those of HULs’ namely Dove and Lux. The matter went to court and didn’t turn out to be in favour of HUL, and gave enough mileage to SebaMed, the objective thus being achieved. Following this, Brinton Pharmaceuticals had launched a #NoPHightingPlease campaign bringing focus to the point that fighting only on the PH levels is of no use as various other aspects are as much or more important while buying a soap. The #NoPHightingPlease campaign was well received by the consumers. Towards it, Brinton has now launched this digital ad that talks about Brintons’ NEOBAR Moisturizing Soap with a unique and smart twist. While being a seriously quirky yet cute video, it also highlights the features of the soap, the features that really matter at the end of the day, namely its ingredients. The digital ad has been spreading fast on social media especially on Facebook and YouTube. <div type="Youtube" id="7NmXilDJ8gc" title="Brinton’s Neobar moisturising soap Digital ad. #NopHightingPlease" thumbUrl="https://i.ytimg.com/vi/7NmXilDJ8gc/mqdefault.jpg"></div> “We wanted to bring out the aspects that really matter while deciding on a soap. But we wanted to do this in an interesting and light manner. Our objective isn’t really to bring anyone down but to help the end consumer make a much more informed decision. The digital video has been spreading like wild fire on its own. I guess at the end of the day the consumer does see through marketing gimmicks and what’s for real. We are happy with the response the digital ad has got so far.” said Rahul Darda, Chairman &amp; Managing Director – Brinton Pharmaceuticals.

Brinton Pharmaceuticals' Neobar Soap makes fun of Sebamed and HUL for fixating on pH levels; remarks that soaps are much more than that

India is set to suffer at least $1 billion (Rs 6,300 crore) of losses in <a href="http://www.businessinsider.in/searchresult.cms?query=pharma">pharmaceutical</a> exports this fiscal year after the <a href="http://www.businessinsider.in/searchresult.cms?query=European+Commission">European Commission</a> banned nearly 700 generic drugs after <a href="http://www.businessinsider.in/searchresult.cms?query=GVK+">GVK </a>Bio allegedly manipulated clinical trials. 
 Director general of <keyword id="6469017" type="UNKNOWN" weightage="80" keywordseo="pharmaceutical">Pharmaceutical</keyword>s Export Promotion Council PV Appaji said, "Majority of those 700 generic drugs are either produced or sourced by the domestic and multinational pharmaceutical companies in India. We estimate that the loss of exports could be $1-1.2 billion this fiscal." 
 A <keyword id="6365809" type="ORGANIZATION" weightage="100" keywordseo="Commerce-ministry">commerce ministry</keyword> official said, "The commerce ministry is not happy with the latest development of the <a href="http://www.businessinsider.in/searchresult.cms?query=commerce+ministry">European Commission</a> going ahead with ban even after series of consultations we had with the respective European agencies. We are reviewing the situation and will decide shortly on the course of action." 
 Appaji said that the commerce ministry is scheduled to organize discussions with the stakeholders in the next couple of days and may lodge a compliant with the global agencies against the <keyword id="59149" type="ORGANIZATION" weightage="100" keywordseo="European-Commission">European Commission</keyword>. 
 
India reportedly exported $15.2 billion or Rs 94,275 crore of pharmaceutical products in 2014-15, with European Union accounting for a fifth or $3 billion. 
 
Image credit: Indiatimes

India may lose Rs 6,300 Crores in pharma
exports

<ul class="summary-list"><li>Fauci said <keyword id="6363818" type="UNKNOWN" weightage="60" keywordseo="Pharma">pharma</keyword> firms can make billions of dollars while giving away drugs to developing nations.</li><li>The pharma industry has lobbied against waiving intellectual property right on COVID-19 vaccines.</li><li>Fauci said the US must help get the rest of the world vaccinated to stop the global pandemic.</li></ul><keyword id="225564" type="PERSON" weightage="60" keywordseo="Anthony-Fauci">Anthony Fauci</keyword> said <keyword id="55215" type="ORGANIZATION" weightage="60" keywordseo="Pharmaceutical-companies">pharmaceutical companies</keyword> can make billions of dollars even when smaller drug companies make generic version of their products.Fauci, the chief medical advisor to President Joe Biden, said transferring the capability of making a <keyword id="8904563" type="UNKNOWN" weightage="60" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> to low- and middle-income countries is an important part of ending the global pandemic. The Biden administration has supported <a href="https://www.businessinsider.com/biden-administration-supports-waiving-ip-rights-for-covid-19-vaccines-2021-5">waiving intellectual property rights</a> for coronavirus <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword>s produced by Johnson &amp; Johnson, <keyword id="44612" type="CITY" weightage="60" keywordseo="Pfizer">Pfizer</keyword>, and <keyword id="4912868" type="PERSON" weightage="60" keywordseo="moderna">Moderna</keyword>. The move allows drug companies in other countries to replicate the vaccine without infringing on trade laws.Pharmaceutical companies <a href="https://www.businessinsider.com/waiving-vaccine-patents-unlikely-to-boost-supplies-experts-say-2021-5">lobbied against waiving patents</a>, but <a href="https://www.businessinsider.com/former-world-leaders-urge-biden-suspend-covid-19-vaccine-patents-2021-4">former world leaders</a> and the <a href="https://www.who.int/news/item/05-05-2021-who-director-general-commends-united-states-decision-to-support-temporary-waiver-on-intellectual-property-rights-for-covid-19-vaccines">World Health Organization</a> have called on the US to waive patents to get vaccines to people in non-wealthy nations quicker."I am very much in favor of protecting the capability of pharmaceutical companies to continue to make a good profit so they can continue to put what it takes to get newer drugs and newer interventions," Fauci said at the Bloomberg Businessweek conference on Thursday. "But there comes a time when the emergent nature of a situation requires doing things that would allow less well developed nations to have access to these interventions. And in this case, that intervention is vaccines for COVID-19."Read more: <a href="https://www.businessinsider.com/billion-dollar-startups-that-are-revolutionizing-healthcare-2021-1">The 24 billion-dollar startups to watch that are revolutionizing healthcare in 2021</a>Fauci said the way to prevent variants from mutating to become resistant to vaccines is to try to expand access to vaccines as much as possible."A very important tenet in virology is that viruses don't mutate if they don't replicate; if you prevent it from spreading from person to person and replicating, it's not going to mutate," he said. "So the easiest way to prevent the emergence of a problematic mutant, which would lead to a variant, is to get as many people throughout the world vaccinated as quickly as you possibly can."The US has been a leader in getting HIV vaccines and AIDS treatment to developing nations in the past, Fauci noted. The immunologist pointed to George W. Bush's President's Emergency Plan for AIDS Relief (PEPFAR) program, which he said has saved 14 to 18 million lives in primarily Southern Africa since 2003.Fauci added drug companies continued to make "billions and billions of dollars" at the same time other drug companies provided generic HIV treatments to people in developing nations.

Fauci said pharmaceutical companies don't lose out when drug formulas are shared with struggling nations

Americans spend much more than people in most other countries on prescribed drugs.That's one finding in a new report, <a href="http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en">Health at a Glance 2015</a>, from the Organisation for Economic Cooperation and Development (OECD). The report noted that the total pharmaceutical spend by OECD countries in 2013 was $800 billion. The US' bill was the highest, and double the OECD average.The data only cover retail spending, or medicines that are prescribed to patients or dispensed directly over the counter. While pharmas are funded by a mix of private and public spending, governments' share fell by about 3.2% on average between 2009 and 2013. After the financial crisis, several countries looked for ways to limit their total spending."Reduction of public pharmaceutical spending in most OECD countries was achieved by a wide range of policy measures, including reforms that have aimed to shift some of the burden of pharmaceutical spending away from the public purse to private payers," the report said. "These measures included the delisting of products (i.e. excluding them from reimbursement) and the introduction or increase of user charges for retail prescription drugs."This chart breaks down spending by country in 2013:<div class="KonaFilter image-container display-table click-to-enlarge"><div><div class="image"><a title_source="OECD" title_caption="" class="zoomin" href="https://static-ssl.businessinsider.com/image/563a0f9ebd86ef16008c718f-960/screen shot 2015-11-04 at 9.00.40 am.png"></a><a href="http://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2015_health_glance-2015-en">OECD</a></div></div></div> <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/science-swallow-pills-properly-easily-2015-8">Scientists have discovered the best way to take pills</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="B3dXRudjotwtxpewzsfdCc1tAyJtomsr" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

Americans are by far spending the most on pharmaceuticals

<div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><a href="http://media.corporate-ir.net/media_files/IROL/22/222170/IsisPharm-IR2013/ISIS-IR-2013.html#I">ISIS Pharmaceuticals</a></div></div></div>Isis Pharmaceuticals <a href="http://www.prnewswire.com/news-releases/isis-pharmaceuticals-changes-name-to-ionis-pharmaceuticals-300195036.html">has changed its name</a> to Ionis Pharmaceuticals. Ionis will begin trading under a new ticker "IONS" on December 22. The company currently trades under the ticker symbol "ISIS."Ionis (pronounced "eye-OH-nis" according to a release) said this new name will represent the company's, "innovative culture and heritage as both the pioneer and leader in the RNA-targeted therapeutic space for the past 26 years."Ionis is a $7 billion biotech company that develops drugs that treat several conditions including cancer and heart conditions. In early trade on Friday, shares of the company were little-changed. Of course, the biggest thing for the company here is that it will no longer be associated with terrorist group ISIS, which was actually the problem. In November, <a href="http://www.businessinsider.com/isis-pharmaceuticals-may-change-name-2015-11">it was reported</a> that the company was considering a name change in the wake of the Paris terror attacks that left over 125 people dead. Back in September 2014, Business Insider's Mike Bird <a href="http://www.businessinsider.com/companies-with-the-name-isis-2014-9">put together a list of companies</a> with the name ISIS as the terror group's notoriety was increasing around the world. Cross one off the list. <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/jim-cramer-fed-interest-rates-james-bullard-dennis-lockhart-2015-12">Jim Cramer blasts the Fed's Bullard and Lockhart for 'not caring about the facts'</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="djcGRqeTpejA4OQnPlzd40fGUMCLR9Pv" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

You Searched For "pharmaceutical" and got 9 results

AstraZeneca is acquiring Alexion Pharmaceuticals in a $39 billion pharmaceutical deal

Kevin Shalvey

Pharmaceuticals: Going Large

The Economist

Glenmark Pharmaceuticals seeks shareholders' approval to raise funds for its expansion plans

BI India Bureau

Ferring Pharmaceuticals has suspended shipments of a key fertility drug, Menopur

Cheryl Teh

Brinton Pharmaceuticals' Neobar Soap makes fun of Sebamed and HUL for fixating on pH levels; remarks that soaps are much more than that

BI India Partner

India may lose Rs 6,300 Crores in pharma exports

BI India Bureau

Fauci said pharmaceutical companies don't lose out when drug formulas are shared with struggling nations

Allana Akhtar

Americans are by far spending the most on pharmaceuticals

Akin Oyedele

Isis Pharmaceuticals is changing its name

Myles Udland

Popular Keywords

Buying Guides